Vor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Vor Biopharma Inc. (NASDAQ:VOR) has received an average rating of “Moderate Buy” from the thirteen analysts that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, five have issued a hold recommendation, six have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $66.1250.

Several brokerages have weighed in on VOR. Zacks Research raised Vor Biopharma from a “strong sell” rating to a “hold” rating in a research report on Tuesday, November 11th. TD Cowen assumed coverage on shares of Vor Biopharma in a report on Wednesday, December 17th. They issued a “buy” rating on the stock. JPMorgan Chase & Co. reduced their target price on shares of Vor Biopharma from $43.00 to $40.00 and set an “overweight” rating for the company in a research note on Friday, December 19th. Citigroup started coverage on shares of Vor Biopharma in a research report on Friday, January 9th. They issued a “buy” rating and a $50.00 target price for the company. Finally, HC Wainwright cut their price target on Vor Biopharma from $55.00 to $32.00 and set a “buy” rating on the stock in a report on Friday, November 14th.

Vor Biopharma Stock Performance

Shares of VOR stock opened at $12.78 on Friday. The firm has a market capitalization of $133.04 million, a price-to-earnings ratio of -0.03 and a beta of 2.02. Vor Biopharma has a one year low of $2.62 and a one year high of $65.80. The company has a 50 day moving average price of $13.55 and a 200 day moving average price of $23.73.

Institutional Trading of Vor Biopharma

Several institutional investors and hedge funds have recently bought and sold shares of VOR. Fcpm Iii Services B.V. acquired a new stake in shares of Vor Biopharma during the 3rd quarter valued at $18,496,000. UBS Group AG boosted its position in Vor Biopharma by 284.8% during the fourth quarter. UBS Group AG now owns 292,118 shares of the company’s stock valued at $3,821,000 after purchasing an additional 216,209 shares during the last quarter. Jane Street Group LLC purchased a new position in Vor Biopharma in the first quarter valued at about $140,000. Geode Capital Management LLC increased its position in Vor Biopharma by 578.3% in the 4th quarter. Geode Capital Management LLC now owns 185,808 shares of the company’s stock worth $2,432,000 after purchasing an additional 158,416 shares during the last quarter. Finally, Millennium Management LLC raised its stake in shares of Vor Biopharma by 122.5% during the 3rd quarter. Millennium Management LLC now owns 24,764 shares of the company’s stock worth $1,207,000 after purchasing an additional 134,764 shares in the last quarter. Institutional investors and hedge funds own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).